<DOC>
	<DOCNO>NCT02941549</DOCNO>
	<brief_summary>The purpose randomise , double-blind , placebo-controlled , parallel group study assess safety efficacy orally administer DS102 capsule versus placebo treatment adult patient Non Alcoholic Fatty Liver Disease ( NAFLD )</brief_summary>
	<brief_title>Safety And Efficacy Study Of Orally Administered DS102 In Patients With NAFLD</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Patients diagnose NAFLD presence hepatic steatosis image histology absence secondary cause Patients ALT ≥ 1.5 ULN &lt; 5 ULN two occasion 7 day apart screen Patients body mass index ( BMI ) 25.0 40.0 kg/m² inclusive . Patients history control obesity control diabetes allow study Patients age 18 75 year inclusive Patients unstable metabolic condition weight change &gt; 5 % 3 month prior inclusion Patients medical/surgical history gastric bypass surgery , orthotopic liver transplant ( OLT ) list OLT Patients uncontrolled diabetes mellitus type 2 , i.e . HbA1c ≥ 9 % ( 75 mmol/mol ) time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>